Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Small but heading for the big time: Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of €1.144 k from Bpifrance as part as the funding granted to support the NICE consortium.

Small but heading for the big time: Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

Paris, France | Posted on October 13th, 2014

Taking into account the development of the Strategic Industrial Innovation (ISI) program and based on the completion of the first milestone "Etape clé 1", Bpifrance has proceed to transfer €1.144 k to Nanobiotix. In January 2014, Nanobiotix has received an initial payment of €461 k from Bpifrance.

Nanobiotix pursued the non-clinical evaluation phase of NBTXR3 with a view to initiating a clinical trial of NBTXR3 in patients suffering from liver cancer. In this population of patients, the aim of using the product is to increase and prolong patients' survival. This non-clinical evaluation phase should allow Nanobiotix to initiate the clinical development in these cancer diseases in 2015.

In July 2013, Bpifrance granted NICE consortium with a funding of almost €9 million, including €2.8 million directly attributable to Nanobiotix through the Strategic Industrial Innovation (ISI) program which is dedicated to accelerate the clinical and industrial development of the Company's lead product NBTXR3 in liver cancers.

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers (Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, H&N cancer, Glioblastoma, Prostate…) via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

About NICE consortium

The NICE (Nano Innovation for CancEr) consortium consists of five public and private partners with in depth expertise in the field of nanomedicine. Its mission is to build the first French platform to accelerate the development and industrialization of nanomedicine.

In addition to Nanobiotix, the consortium includes Onxeo (ex BioAlliance Pharma) which is developing Livatag®; CEA-Leti, the developer of Lipidots® platform nanoparticles; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.

The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).

Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should” or “will”, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the 2013 financial annual report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to developments in general economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.

For more information, please click here

Contacts:
Nanobiotix
Head of Communication and Public Affairs
Sarah Gaubert
+33 (0)1 40 26 07 55



NewCap
Financial communication and investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
+33 (0)1 44 71 98 53



NewCap
Media relations (France)
Annie-Florence Loyer
+33 (0) 1 44 71 94 93



Instinctif Partners
Media relations (Outside France)
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Cancer

University of Toronto researchers discover new lipid nanoparticle that shows muscle-specific mRNA delivery, reduces off-target effects: Study findings make significant contribution to generating tissue-specific ionizable lipids and prompts rethinking of mRNA vaccine design princi December 8th, 2023

Super-efficient laser light-induced detection of cancer cell-derived nanoparticles: Skipping ultracentrifugation, detection time reduced from hours to minutes! October 6th, 2023

The medicine of the future could be artificial life forms October 6th, 2023

Chung-Ang University researchers develop novel DNA biosensor for early diagnosis of cervical cancer: The electrochemical sensor, made of a graphitic nano-onion/molybdenum disulfide nanosheet composite, detects human papillomavirus (HPV)-16 and HPV-18, with high specificity September 8th, 2023

Govt.-Legislation/Regulation/Funding/Policy

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Optically trapped quantum droplets of light can bind together to form macroscopic complexes March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

Research partnerships

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024

Development of zinc oxide nanopagoda array photoelectrode: photoelectrochemical water-splitting hydrogen production January 12th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project